Australia Clears Nexstim Neuromodulation Depression Treatment
Neuromodulation firm Nexstim has received regulatory clearance for its SmartFocus TMS system for treating major depressive disorder (MDD) in Australia.
You may also be interested in...
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.